The Case in Point on Competition in the Market for Generic

Multiple Choice

The Case in Point on Competition in the Market for Generic Prescription Drugs suggests that:

A) there is little if any price difference between branded prescription drugs and generic prescription drugs because of imperfect information.
B) there is little if any price difference between branded prescription drugs and generic prescription drugs because the goods are essentially identical and the firms are price takers.
C) branded prescription drugs are less expensive than their generic counterparts because of economies of scale.
D) generic prescription drugs are less expensive than their branded counterparts because of the ease of entry into the market.